LncRNA RP1-13P20.6调控Vav1基因抑制结直肠癌细胞增殖及侵袭效应 的机制研究
批准号:
81902447
项目类别:
青年科学基金项目
资助金额:
21.0 万元
负责人:
刘晶晶
依托单位:
学科分类:
H1805.肿瘤表观遗传
结题年份:
2022
批准年份:
2019
项目状态:
已结题
项目参与者:
--
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
LncRNA在多种疾病中发挥重要调节作用,申请者发现并报道lncRNA RP1-13P20.6在结直肠癌组织中异常低表达并发挥抑癌作用。进一步研究结果证实RP1-13P20.6靶向结合Vav1基因启动子区,发挥负向调节作用。生物信息学分析显示转录因子C/EBP-β与Vav1基因启动子区有多个结合位点,且RP1-13P20.6含有C/EBP-β的多个反应元件。因此我们推测RP1-13P20.6介导转录因子C/EBP-β失活、抑制Vav1基因表达,进而抑制结直肠癌细胞的增殖与侵袭。本研究拟利用RIP实验、双荧光素酶实验及裸鼠成瘤等在分子、细胞、动物及临床水平验证RP1-13P20.6对Vav1的调控作用及其对结直肠癌发生发展的影响,探索RP1-13P20.6发挥抑癌作用的分子机制,进一步丰富非编码RNA参与疾病调控的理论研究,并可能为结直肠癌的治疗提供新靶点及理论基础,具有一定科学意义。
英文摘要
LncRNA is a kind of non-coding RNA with regulatory function. We found that lncRNA RP1-13P20.6 was down-regulated in colorectal cancer tissues and inhibited the proliferation and invasion of colorectal cancer cells. Using transcription-associated trap, we found that oncogene Vav1 was one of the targets of RP1-13P20.6. The transcription and translation level of Vav1 was decreased significantly when RP1-13P20.6 was overexpressed. Bioinformatics analysis showed that transcription factor C/EBP-β had multiple binding sites with promoter region of Vav1 gene and C/EBP-β was one of the target proteins of RP1-13P20.6. Therefore, we hypothesis that RP1-13P20.6 inactivated transcription factor C/EBP-β and down-regulated the expression of Vav1 gene, and then inhibited the proliferation and invasion of colorectal cancer cells. We aim to verify the mechanisms of RP1-13P20.6 in regulating Vav1 and the effects on oncogenesis and the development of colorectal cancer in molecular, cellular, animal and clinical level, and try to explore the molecular mechanisms of how RP1-13P20.6 suppress tumor growth. This will further enrich the theory of the regulatory roles of lncRNAs participating in multiple diseases and may provide a new target for the treatment of colorectal cancer.
LncRNA在多种疾病中发挥重要调节作用,本项目研究发现lncRNA RP1-13P20.6通过负向调控vav1基因进而抑制结直肠癌细胞的增殖和侵袭。进一步的研究证实了lncRNA RP1-13P20.6与转录因子C/EBP-β的直接结合作用。同时,我们通过质谱分析发现有427个蛋白在lncRNA RP1-13P20.6过表达后发生表达差异,显著下调的蛋白包括DNAJB12、ENO1、CDK6、CDK4、HK2、S100A4、IFITM家族中的IFITM3、IFITM2及IFITM1等,通过GO分析及有氧糖酵解相关实验我们发现lncRNA RP1-13P20.6主要通过调控结直肠癌细胞有氧糖酵解而发挥抑癌作用。另外,我们针对IFITM家族的IFITM10进行了进一步研究,结果发现IFITM10在胃肠癌的癌组织中表达上调,并发挥促癌作用。本课题组在前期工作基础上,探索RP1-13P20.6发挥抑癌作用的分子机制,进一步丰富了非编码RNA参与疾病调控的理论研究。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Highly expressed IFITM10 is associated with early diagnosis and T stage of gastric cancer.
高表达 IFITM10 与胃癌早期诊断及 T 分期相关
DOI:10.21037/tcr-20-2333
发表时间:2021-01
期刊:Translational cancer research
影响因子:0.9
作者:Liu Y;Liu J;Tian Z;Zhang Z;Liu T;Chen C;Tang X;Zhu J
通讯作者:Zhu J
国内基金
海外基金















{{item.name}}会员


